Just noticed one analyst has updated the price target to $47, which brought the average to $41. Not sure for how long has it been there, and nothing critical, but not bad to have. We all know what are the critical triggering events lying ahead.
It sure seems to hate $39 though.
Well. Listened to the presentation today. Not much new which we have not already known, but the following statement (take a look at the slide deck on their website) is singularly important:
(Monovisc is still) "Pending FDA PMA amendment review."
Accordingly, the hope for its final approval and share ascending from here, albeit elusive, remains well alive.